15 October 2019 - Cabometyx demonstrated a statistically significant, 52% reduction in the risk of progression or death compared with sunitinib, giving Canadian patients with intermediate or poor risk a new oral first-line treatment option in their fight against advanced kidney cancer.

Ipsen today announced the Health Canada approval of Cabometyx (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with advanced renal cell carcinoma (aRCC), the most common type of kidney cancer.

This approval was based on the CABOSUN trial which demonstrated that Cabometyx significantly prolonged progression-free survival compared to sunitinib in treatment naïve aRCC patients with intermediate or poor-risk disease.

Read Ipsen press release